Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07031765 · ClinicalTrials.gov registry record · Phase 1

Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma

A Phase 1 study of Ependymoma and Oligodendroglioma, sponsored by University of Florida.

Active
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT07031765 is a Phase 1 study of Ependymoma and Oligodendroglioma that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 12 participants, below the 104-participant average among 20 other Ependymoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07031765, a Phase 1 study of Ependymoma and Oligodendroglioma, is active but no longer recruiting, sponsored by University of Florida.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This is a Phase I study of ex vivo expanded CD34+ hematopoietic stem cells (exHSCs) plus nivolumab in pediatric patients with histologically confirmed diagnosis of a non-brainstem high-grade glioma (NB-HGG, WHO Grade III or IV astrocytoma, oligodendrogliomas, oligoastrocytomas, ependymomas) that is recurrent, progressive or refractory following radiotherapy with or without chemotherapy. Patients must be candidates for standard of care surgical resection or biopsy.

Conditions Studied

Ependymoma Oligodendroglioma Recurrent High Grade Glioma Oligoastrocytoma Grade IV Astrocytoma Grade III Astrocytoma

Interventions

  • DRUG Nivolumab
  • BIOLOGICAL exHSC
  • PROCEDURE Resection or biopsy

Study Locations (1)

Florida

  • UF Health Shands Children's Hospital/Shands Hospital - Gainesville

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2025-07-25
Est. Completion 2032-12
Phase Phase 1

Sponsor

University of Florida

1,106 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07031765

The ClinicalTrials.gov registry entry for NCT07031765 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 20 other Ependymoma trials with a reported enrollment target (88% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Ependymoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.

NCT07031765 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT07031765 about?

NCT07031765 is a clinical study titled "Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma". This is a Phase I study of ex vivo expanded CD34+ hematopoietic stem cells (exHSCs) plus nivolumab in pediatric patients with histologically confirmed diagnosis of a non-brainstem high-grade glioma (NB-HGG, WHO Grade III or IV astrocytoma, oligodendrogliomas, oligoastrocytomas, ependymomas) that is ...

What is the current status of trial NCT07031765?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-07-25. Estimated completion is 2032-12.

What conditions does trial NCT07031765 study?

This clinical trial studies the following conditions: Ependymoma, Oligodendroglioma, Recurrent High Grade Glioma, Oligoastrocytoma, Grade IV Astrocytoma.

What interventions are being tested in trial NCT07031765?

The interventions under investigation include: Nivolumab (DRUG), exHSC (BIOLOGICAL), Resection or biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT07031765?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07031765 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ependymoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ependymoma

All registered trials for this condition

Oligodendroglioma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.